Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model

• Published in: Journal of Alzheimer's Disease
• Main Author: Nasri W.N.W.; Makpol S.; Mazlan M.; Tooyama I.; Ngah W.Z.W.; Damanhuri H.A.
• Format: Article
• Language: English
• Published: IOS Press 2019
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071288588&doi=10.3233%2fJAD-180496&partnerID=40&md5=5aa2c60f62faff9d5dfd7eda8b1dee39

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by loss of memory and other cognitive abilities. AD is associated with aggregation of amyloid-β (Aβ) deposited in the hippocampal brain region. Our previous work has shown that tocotrienol rich fraction (TRF) supplementation was able to attenuate the blood oxidative status, improve behavior, and reduce fibrillary-Type Aβ deposition in the hippocampus of an AD mouse model. In the present study, we investigate the effect of 6 months of TRF supplementation on transcriptome profile in the hippocampus of APPswe/PS1dE9 double transgenic mice. TRF supplementation can alleviate AD conditions by modulating several important genes in AD. Moreover, TRF supplementation attenuated the affected biological process and pathways that were upregulated in the AD mouse model. Our findings indicate that TRF supplementation can modulate hippocampal gene expression as well as biological processes that can potentially delay the progression of AD. © 2019-IOS Press and the authors. All rights reserved.